[Pe-070] English Poster Session 070「Clinical trials and Drug development」

[Pe-070-4] Phase 1/2 trial of bromocriptine in Alzheimer's disease with presenilin 1 mutations (REBRAnD)

Haruhiko Banno¹, Taro Okunomiya¹, Takayuki Kondo¹, Yoko Amino¹, Akiyoshi Nakakura¹, Harue Tada¹, Satoshi Morita¹, Akihiro Shindo², Takakuni Maki¹, Manabu Ikeda³, Yuishin Izumi⁴, Kazutomi Kanemaru⁵, Kenji Ishii⁵, Kazue Shigenobu⁶, Yoshihide Sunada⁷, Shinobu Kawakatsu⁸, Noriyuki Matsukawa⁹, Ryosuke Takahashi¹, Hidekazu Tomimoto², Haruhisa Inoue¹, REBRAnD investigators REBRAnD investigators^1,2,3,4,5 (1.CiRA/iACT/Department of Neurology, Kyoto University, Japan, 2.Department of Neurology, Mie University, Japan, 3.Department of Psychiatry, Osaka University, Japan, 4.Department of Neurology, Tokushima University, Japan, 5.Department of Stroke/Neurology, Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Japan, 6.Department of Neuropsychiatry, Asakayama Hospital, Japan, 7.Department of Neurology, Kawasaki Medical School, Japan, 8.Department of Neuropsychiatry, Aizu Medical Center, Fukushima Medical University, Japan, 9.Department of Neurology, Nagoya City University, Japan)